Royal Bank Of Canada Increases Corteva (NYSE:CTVA) Price Target to $89.00

Corteva (NYSE:CTVA) had its price objective increased by analysts at Royal Bank Of Canada from $80.00 to $89.00 in a research report issued on Thursday, MarketBeat Ratings reports. The brokerage currently has an “outperform” rating on the stock. Royal Bank Of Canada’s price objective suggests a potential upside of 22.54% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on the company. Mizuho increased their target price on Corteva from $78.00 to $80.00 and gave the stock an “outperform” rating in a report on Friday, January 16th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Corteva in a research note on Monday, December 29th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Corteva from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, November 6th. Citigroup increased their target price on shares of Corteva from $74.00 to $80.00 and gave the stock a “neutral” rating in a research report on Thursday. Finally, JPMorgan Chase & Co. lowered shares of Corteva from an “overweight” rating to a “neutral” rating and boosted their price target for the company from $75.00 to $77.00 in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $82.37.

Corteva Trading Up 0.2%

Shares of Corteva stock opened at $72.63 on Thursday. Corteva has a 52-week low of $53.40 and a 52-week high of $77.41. The firm has a market capitalization of $49.08 billion, a PE ratio of 45.97, a price-to-earnings-growth ratio of 1.84 and a beta of 0.75. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.43 and a quick ratio of 1.07. The company’s fifty day moving average price is $68.82 and its two-hundred day moving average price is $68.42.

Corteva (NYSE:CTVA) last issued its earnings results on Tuesday, February 3rd. The company reported $0.22 earnings per share for the quarter, meeting the consensus estimate of $0.22. Corteva had a net margin of 6.29% and a return on equity of 9.06%. The business had revenue of $3.91 billion for the quarter, compared to analyst estimates of $4.23 billion. During the same period in the previous year, the business earned $0.32 EPS. The firm’s revenue was down 1.7% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, analysts expect that Corteva will post 2.96 EPS for the current year.

Institutional Trading of Corteva

A number of hedge funds and other institutional investors have recently modified their holdings of CTVA. Brighton Jones LLC increased its stake in shares of Corteva by 307.2% in the 4th quarter. Brighton Jones LLC now owns 15,588 shares of the company’s stock valued at $888,000 after buying an additional 11,760 shares during the period. Woodline Partners LP boosted its holdings in Corteva by 40.3% in the first quarter. Woodline Partners LP now owns 57,919 shares of the company’s stock valued at $3,645,000 after acquiring an additional 16,644 shares during the last quarter. Wealthcare Advisory Partners LLC acquired a new stake in Corteva in the second quarter worth about $213,000. KLP Kapitalforvaltning AS raised its holdings in Corteva by 6.2% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 251,676 shares of the company’s stock worth $18,757,000 after purchasing an additional 14,600 shares during the last quarter. Finally, Joel Isaacson & Co. LLC acquired a new position in Corteva during the 2nd quarter valued at about $228,000. Institutional investors and hedge funds own 81.54% of the company’s stock.

Corteva News Roundup

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Several sell‑side firms lifted targets and kept bullish ratings, signaling analyst confidence in longer‑term upside: Deutsche Bank to $90 (buy), Wolfe Research to $86 (outperform), and RBC to $89 (outperform). Deutsche Bank raise Wolfe Research raise RBC raise
• Positive Sentiment: Brokerage consensus remains constructive (consensus “Moderate Buy”), which supports demand for the shares despite near‑term noise. Consensus Moderate Buy
• Positive Sentiment: Strategic commentary highlights Corteva’s expanding role in global agriculture and technology leadership—positive for medium‑term growth expectations. Corteva expands role
• Neutral Sentiment: Analyst views are mixed across publications — some highlight long‑term upside tied to licensing and settlements, while others argue valuation limits near‑term gains. Investors should weigh catalyst timing. Bull case analysis Conflicting analyst views
• Neutral Sentiment: Technical analysis pieces warn of a key structural test — useful for traders but not definitive for fundamentals; could increase short‑term volatility. Technical caution
• Negative Sentiment: Q4 results missed revenue expectations (seasonal timing and weaker crop‑protection/seed demand); revenue miss and a wider loss drove an after‑hours selloff. Those operational misses are the main near‑term headwind. Q4 revenue miss After‑hours fall
• Negative Sentiment: JPMorgan downgraded Corteva from overweight to neutral (citing valuation/limited near‑term upside), which can cool momentum among institutional buyers. JPMorgan downgrade
• Negative Sentiment: Market reaction to the earnings miss (seasonal timing) and mixed guidance elements increases short‑term uncertainty even as analysts argue for longer‑term upside — expect higher intraday volatility. Seasonal timing impact

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.